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Abstract
Background and Objectives: Glutathione S-transferases (GSTs) are multifunctional enzymes that play a key role in the
detoxification of varieties of both endogenous products of oxidative stress and exogenous carcinogens.
Methods: In this meta-analysis, twenty-five studies were identified by searching PubMed, EMBASE, ISI Web of Science and
CBM databases: 23 evaluated GSTM1 and 19 evaluated GSTT1. Crude odds ratios with corresponding 95% confidence
intervals were used to estimate the association between GSTM1 and GSTT1 polymorphisms and risk of cervical neoplasia.
Subgroup analyses were conducted by pathological history, ethnicity, source of DNA for genotyping, quality score, and
matching variable.
Results: The null genotypes of GSTM1 and GSTT1 polymorphisms were associated with a significantly increased risk of
cervical neoplasia (for GSTM1: OR=1.40; 95%CI, 1.19–1.65; for GSTT1: OR=1.30; 95%CI, 1.05–1.62, respectively). Subgroup
analyses showed that the null genotype of GSTM1 increased the risk of cervical neoplasia in Asians, studies with DNA
isolation from white blood cells and tissue samples, both high and low quality studies, and matched studies. In GSTM1-
GSTT1 interaction analysis, individuals with dual null genotype were associated with a significantly increased risk of cervical
neoplasia (OR=1.72; 95%CI, 1.18–2.51).
Conclusion: These findings indicate that GSTM1 and GSTT1 polymorphisms, particularly GSTM1-GSTT1 interaction, may play
critical roles in the development of cervical neoplasia. A conservative manner should be adopted to interpret these results
because of obvious heterogeneity between-study, unadjusted data, and relatively small sample size in this meta-analysis.
Well designed studies with larger sample size are of great value to confirm these results.
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Introduction
Cervical cancer is the second most frequent cancer among
women worldwide, with approximately 493,000 new cases dia-
gnosedand274,000deathsoccurringeachyear(2002estimates)[1].
Despite substantial declines in the incidence and mortality of
cervical cancer in developed countries, more than 80% of all
cervical cancer occurs in developing countries [1,2]. The burden of
cervical cancer is not only the high incidence rates in women in
some developing countries, but also the societal impact because a
fractionofpatientswhosuffered fromthediseaseintheir30’sor40’s
are still raising or supporting families.
It is well established that human papilloma virus (HPV) infection
is a necessary but insufficient event for the development of cervical
cancer [3–6], because not all HPV-infected patients do develop
cervical cancer. Therefore, many research efforts were taken to
identify cofactors for cervical cancer development. To date, the
major risk cofactors have been confirmed by large meta-analysis,
including smoking, multiple sexual partners, increasing parity,
earlier age at first intercourse (#20 years), and long duration of oral
contraceptive use [7–9]. However, it is currently accepted that the
development of cervical cancer is the result of complex interaction
of both environmental and genetic factors [10]. Epidemiological
evidence has shown that there is a significant familial clustering
among biological relatives. The familial relative risk for individuals
with biological full-sisters of cervical cancer cases is almost twice as
high as those with biological full-sisters of controls [11–13].
Recently, several meta-analysis studies revealed that a polymorphic
variant of the tumor suppressor P53 (Pro72Arg) may represent a
genetic marker for cervical carcinogenesis [14–17].
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genetic variants have been explored extensively as a predictive
factor for cancer prognosis [18]. GSTs are a family of enzymes
with a crucial function in the detoxification of a variety of both
endogenous products of oxidative stress and exogenous carcino-
gens [19,20]. In humans, GST super-family consists of many
cytosolic, mitochondrial, and microsomal proteins. The cytosolic
family has been assigned to eight distinct classes: alpha, kappa, mu,
omega, pi, sigma, theta, and zeta [21]. The mu class of GSTs,
encoded by the GSTM1 gene, is located on the short arm of
chromosome 1 (1p13.3) [22]. The theta class of GSTs, encoded
by the GSTT1 gene, is locate on the long arm of chromosome 22
(22q11.23) [23]. Both GSTM1 and GSTT1 gene exhibit an
inherited homozygous deletion polymorphism (null genotype) that
is associated with an absence of enzyme activity. Individuals with
homozygous deletion polymorphism are considered to be at
increased risk for malignancies due to reduced efficiency in pro-
tection against environmental carcinogens [18,24].
In 1994, Warwick et al. explored for the first time the
association between GSTM1 and GSTT1 polymorphisms and the
risk of cervical neoplasia, and found that the combination of three
factors (i.e., GSTM1 or GSTT1 null, CYP2D6 EM, and smoking)
appeared significantly different frequency in cases and controls
[25,26]. Subsequently, a large number of epidemiological studies
have been addressed to evaluate the association between GSTM1
and GSTT1 homozygous deletion polymorphisms and risk of
cervical neoplasia in diverse ethnicities [25–49]. However, this
issue remains controversial because of inconsistent results among
different studies. The possibilities for this discrepancy may be that
some positive results might occur by chance and some negative
findings might be caused by insufficient statistical power with small
sample size. Additionally, different experimental design and
selection bias should also be considered.
In order to provide strong evidence of the effects of GSTM1 and
GSTT1 polymorphisms on cervical neoplasia risk, we carried out a
quantitative meta-analysis by combining data from all published
case-control studies. Additionally, gene-gene and gene-environment
interactions have also been examined in this meta-analysis.
Materials and Methods
Selection of Published Studies
We identified all publications by conducting computer-based
searches of PubMed, EMBASE, ISI Web of Science, and CBM
databases without language restrictions, using the following search
algorithm: (‘‘cervical cancer’’ or ‘‘cervical carcinoma’’ or ‘‘uterine
cervix cancer’’ or ‘‘CC’’ or ‘‘cervical neoplasia’’) and (‘‘glutathione
S-transferase’’ or ‘‘GST’’ or ‘‘GSTM’’ or ‘‘GSTM1’’ or ‘‘GSTT’’
or ‘‘GSTT1’’) and (‘‘polymorphism’’ or ‘‘polymorphisms’’ or
‘‘variant’’). The literature search was performed up to Aug 2010.
The inclusion criteria were: (a) case-control studies that investi-
gated the association between GSTM1 and/or GSTT1 polymor-
phism and risk of cervical neoplasia; (b) presenting original data for
the calculation of odds ratios (ORs) with corresponding 95%
confidence intervals (95%CIs).
One hundred and fifty-four articles were identified by searching
PubMed, EMBASE, ISI Web of Science and CBM databases.
Eighty-four studies were excluded after screening the title or
abstract (67 were not cervical cancer; eight were no polymorphism;
six were not human studies; three were not case-control studies).
Then full-text articles were retrieved for assessment in detail. Forty-
three were excluded with reasonsfor not cervical cancer (n=23), no
GSTM1 and/or GSTT1 polymorphism (n=13), no available data
(n=5) and review articles (n=2). Additionally, we excluded two
studies because the results were duplicated in subsequent publica-
tions [50,51]. Finally, a total of 25 studies were included in this
meta-analysis (Figure S1). Of the 25 studies, 23 studies investigated
the association between GSTM1 polymorphism and risk of cervical
neoplasia and 19 studies investigated the association between
GSTT1 polymorphism and risk of cervical neoplasia.
The groups of pathologic type were set according to the report by
Klug et al. [17]. Briefly, the selected studies in this analysis were
composed of unclear type of cervical cancer, squamous cell
carcinoma (SCC), adenocarcinoma (AC), adenosquamous carcino-
ma, high-grade lesions (HGL, containing high-grade squamous
intraepithelial lesions and cervical intraepithelial lesions grades 2
and 3) and low-grade lesions (LGL, containing low-grade squamous
intraepithelial lesions and cervical intraepithelial lesions grade 1).
This study was approved by the ethics committee of Sichuan
University. The data included in this study was taken from litera-
tures,and thuswrittenconsentgivenbythepatientswasnot needed.
Data Extraction
Two independent researchers (Gao and Pan) extracted raw data
according to the inclusion criteria. The following information was
collected from each study using a data extraction form: the
surname of the first author, date of publication, country of origin,
year of sample collection, ethnicity, characteristics of cases and
controls, DNA source for genotyping, matching variables, number
of cases and controls, genotype distribution of cases and controls,
and quality control for genotyping assay. Additionally, we
extracted, if available, the genotype frequency of cases and
controls based on age (.40 or #40 years), smoking status
(smoking or non-smoking) and HPV infection status (HPV positive
or HPV negative). Given that there was no distribution of null/
present heterozygote in each single study selected, the Hardy-
Weinberg equilibrium (HWE) test could not be conducted. To
ensure the accuracy of data extraction, the original extraction
information was checked by Li, and discordant results were settled
through discussion among the three authors.
Quality Score Evaluation
Three investigators (Gao, Pan, and Li) independently assessed
the quality of included studies based on a predetermined rating
scale (Table S1) that was amended from previous studies [52–54].
Any discrepancies were resolved by consultation with the other
authors in the team group, and an ultimate decision was made by
the majority of the votes cast. A numerical score ranging from 0 to
12 was assigned as a quantitative measure of literature quality.
Studies were categorized as ‘‘high quality’’ if the quality score was
$7; otherwise, studies were categorized as ‘‘low quality’’.
Statistical Analysis
We used crude ORs with corresponding 95% CIs as a measure
of the association between GSTM1 and GSTT1 polymorphisms
and risk of cervical neoplasia. Study-specific ORs comparing null
genotype versus present genotype were combined using random-
effects model (the DerSimonian and Laird) or fixed-effects model
(the Mantel–Haenszel method), which was determined by the Q-
test and I
2 statistics [55,56]. If the P value for heterogeneity was
#0.10 or I
2$50%, indicating a high extent of heterogeneity
between studies, we used the DerSimonian and Laird method to
evaluate the summary ORs. In contrast, if the P value for
heterogeneity was .0.10 and I
2,50%, indicating an absence of
heterogeneity between studies [57,58], we used the Mantel–
Haenszel method to evaluate the summary ORs.
Subgroup analyses were conducted by pathological history
(squamous cell cervical carcinoma, adenocarcinoma and adeno-
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LGL, and mixed), ethnicity (Asian, Caucasian, and mixed), source
of DNA for genotyping (white blood cells, exfoliated cervical cells,
tissue sample, and mixed), quality score (high versus low),
matching according to age (matched versus unmatched), smoking
status (smoking versus non-smoking) and HPV infection status
(HPV positive versus HPV negative). Additionally, we evaluated
the effect of the GSTM1-GSTT1 interaction on cervical neoplasia
compared with null/null versus present/present, null/null versus
present/null, null/null versus null/present, null/present versus
present/null, null/present versus present/present, and present/
null versus present/present.
Logistic meta-regression was used to investigate possible sources
of heterogeneity across studies. To determine the reliability of the
outcomes in the meta-analysis, a sensitivity analysis was performed
by exclusion an individual study each time. An evaluation of
publication bias was carried out with funnel plot for visual
inspection and Egger’s regression asymmetry test [59]. All analyses
were conducted in STATA software, version 10.0 (STATA Corp.,
College Station, TX).
Results
Characteristics of Studies
The baseline characteristics of the included studies are shown in
Tables S2 and S3.
GSTM1 Polymorphism. Totally, 23 studies met the
inclusion criteria and were selected in this meta-analysis with
2,610 cases and 3,084 controls. Cases consisted of 32.5% patients
with cervical cancer (histology not specified), 31.9% patients with
SCC, 14.2% patients with HGL, 8.6% patients with LGL, 5.0%
patients with SIL (unknown grade), 4.7% patients with both ICC
and HGL and 3.0% patients with AC. Most of the controls
(86.8%) were normal participants. There were sixteen studies of
Asians, six studies of Caucasians, and two studies of mixed
ethnicities that included more than one ethnicity. DNA used for
GSTM1 genotyping was extracted from white blood cells in 15
studies (62.5%). 17 studies (70.8%) mentioned genotyping quality
control methods, mainly using an internal control. However, only
six studies (25.0%) reported smoking status and only four studies
(16.7%) detected HPV infection status.
GSTT1 Polymorphism. A total of 19 studies were included
in the meta-analysis with 2,092 cases and 2,054 controls. Cases
consisted of 27.1% patients with cervical cancer (histology not
specified), 30.5% patients with SCC, 15.9% patients with HGL,
8.6% patients with LGL, 6.3% patients with SIL (unknown grade),
5.9% patients with both ICC and HGL and 5.8% patients
with AC. Most of the controls (85.5%) were normal participants.
Twelve studies were conducted in Asia; four in Europe; two
in America and one in South America. Similar to GSTM1
polymorphism, most studies (68.4%) mentioned genotyping qua-
lity control methods, but only about 20% studies reported smoking
status and HPV infection status.
Meta-analysis of GSTM1 Polymorphism and Cervical
Neoplasia
The evaluations of the association between GSTM1 polymor-
phism and cervical neoplasia risk are summarized in Table S4.
The null genotype of GSTM1 polymorphism was associated
with a significantly increased risk of cervical neoplasia when
compared with present genotype (OR=1.40; 95%CI, 1.19–1.65).
When stratified by pathologic types, significantly elevated risks
were observed in unknown type of cervical cancer (OR=1.54;
95%CI, 1.16–2.04) and mixed group (OR=1.98; 95%CI,
1.46–2.68) but not in groups of SCC, HGL, LGL and AC. In
the subgroup analysis by ethnicity, significantly increased risks
were observed in Asian population (OR=1.60; 95%CI, 1.29–
1.98) but not in Caucasian and mixed populations (Figure S2).
Subgroup analysis on the basis of DNA source showed that the
increased risks were found in studies that DNA was extracted from
white blood cells (OR=1.29; 95%CI, 1.08–1.55) or tissue sample
(OR=3.14; 95%CI, 1.90–5.19). No excess risk was found in
studies that DNA was extracted from exfoliated cervical cells.
Subgroup analysis was also performed according to quality
criteria. The combined results showed that the null genotype
was associated with an increased risk of cervical neoplasia in
studies whether the quality score was high (OR=1.31; 95%CI,
1.06–1.62) or low (OR=1.49; 95%CI, 1.16–1.91). The increased
risks were also found in studies in which controls were frequency
matched to cases by age (OR=1.54; 95%CI, 1.22–1.95), but not
in studies in which controls were unmatched to cases by age.
Additionally, subgroup analysis by age presented the results that
the null genotype was associated with an increased risk of cervical
neoplasia in studies with patients of age #40 years (OR=2.02;
95%CI, 1.30–3.14).
Meta-analysis of GSTT1 Polymorphism and Cervical
Neoplasia
The evaluations of the association of GSTT1 polymorphism and
cervical neoplasia risk are listed in Table S5.
Thenullgenotype ofGSTT1polymorphism was associated with a
significantly increasedriskofcervicalneoplasia (OR=1.30;95%CI,
1.05–1.62) and unknown type of cervical cancer (OR=1.49;
95%CI, 1.02–2.19), while the association was not observed in
subgroup analyses according to ethnicity, DNA source, and quality
criteria (Figure S3).
Meta-analysis of GSTM1-GSTT1 Interaction with Cervical
Neoplasia
The evaluations of the association between GSTM1-GSTT1
interaction and cervical neoplasia risk are shown in Table S6.
The dual null genotype was associated with a significantly
increased risk of cervical neoplasia when compared with the dual
present genotype (OR=1.72; 95%CI, 1.18–2.51) (Figure S4). No
significantly increased risk was detected in any other comparison
group.
Interaction between GSTM1 and GSTT1 and
Environmental Exposure
There were six literatures which investigated the impact of
interaction between GSTM1 polymorphism and smoking on
cervical neoplasia, and there were four literatures which
investigated the impact of interaction between GSTT1 polymor-
phism and smoking on cervical neoplasia. The effect of interaction
between GSTM1 polymorphism and HPV infection status on
cervical neoplasia was reported in four studies, and the effect of
interaction between GSTT1 polymorphism and HPV infection
status on cervical neoplasia was reported in five studies. No
increased risks were found in the interaction between GSTM1 and
GSTT1 polymorphisms and environmental exposure (i.e., smoking
status and HPV infection status) (Tables S4 and S5).
Heterogeneity Analysis
The findings of Q-tests and I
2 statistics were shown in Tables
S4, S5, and S6. Significant heterogeneity across studies was
present in overall analyses (for GSTM1, I
2=53.3%; for GSTT1,
I
2=59.1%) and subgroup analyses. We explored several possible
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ethnicity, sample size, DNA source for genotyping and quality
score. However, none of these variables could explain the
heterogeneity.
Sensitivity Analysis and Publication Bias
To assess the effect of individual study on the overall meta-
analysis estimate, we excluded one study at a time, and the
exclusion of any single report did not alter the significance of the
final decision, suggesting that the outcomes were robust. Funnel
plot and Egger’s test were used to assess publication bias of
literatures on cervical neoplasia. No evidence of publication bias
was observed in all comparison groups (P.0.05).
Discussion
The glutathiones S-transferases (GSTs) are the most important
parts of phase II superfamily of metabolism enzymes. In humans,
there are several GST classes that were encoded by distinct gene
families [21]. Among them, GSTM1 and GSTT1 should be pointed
out because a polymorphic deletion of these genes may influence
the enzyme activity, and eventually increased vulnerability to
genotoxic damage [60,61]. Based on these backgrounds, the
association has been intensively investigated between GSTM1 and
GSTT1 polymorphisms and risk of cervical neoplasia [25–49].
Unfortunately, most of the studies have only a few hundred of
participants, even less, which is too small to evaluate the overall
effects precisely. Meta-analysis has been considered to be a
powerful tool to overcome this problem by combining the results
from independent studies together. In this meta-analysis, we found
that the null genotypes of GSTM1 and GSTT1 polymorphisms
were associated with a significantly increased risk of cervical
neoplasia, suggesting that GSTM1 and GSTT1 polymorphisms
may be involved in the development of cervical neoplasia.
Notably, the between-study heterogeneity was observed in both
overall analyses and some subgroup analyses, further studies
therefore are warranted to confirm these findings.
After subgroup analysis according to ethnicity, significantly
increased risks were observed in Asian population but not in
Caucasian and mixed populations. The possibilities of the
conflicting results among diverse ethnicities may be that the
GSTM1 and GSTT1 polymorphisms have different effects on the
risk of cervical neoplasia in different genetic backgrounds and
environment which they exposed to. The major difference in the
distribution of GSTM1 and GSTT1 polymorphisms has been
reported among control groups in 2001. The frequency of GSTM1
null genotype was 53.1% (42.0–60.0%) in Caucasians, 52.9%
(42.0–54.0%) in Asians, and 26.7% (16.0–36.0%) in Africans. The
frequency of GSTT1 null genotype was 19.7% (13.0–26.0%) in
Caucasians and 47.0% (35.0–52.0%) in Asians [62]. Additionally,
the small sample size should also be taken into consideration
because limited sample size may have not enough statistical power
to detect a real effect or generate a fluctuated estimation. At
present, limited studies investigated the association between
GSTM1 and GSTT1 polymorphisms and the risk of cervical
neoplasia in Caucasian and mixed populations. Therefore, well-
designed studies with thousands of sample size are of great value to
confirm this finding in Caucasians and other ethnic populations.
When stratified based on the source of DNA for GSTM1 and
GSTT1 genotyping, the null genotype of GSTM1 significantly
increased the cervical neoplasia risk in studies that the polymor-
phism was determined from white blood cells rather than from
exfoliated cervical cells. The difference of studies with DNA
isolation from exfoliated cervical cells tended to be significant
(P=0.057). It is likely that the potentially negative results were
caused by small sample size with only 299 cases and 405 controls
available in this meta-analysis. Another important issue is the
source of cell used for DNA analysis. DNA isolation from different
cell types may influence performance of genotyping, and even-
tually, lead to the conflicting results.
It is absolutely pivotal for a meta-analysis to assess the quality
of literatures included. Currently, no standard quality score
method was developed to evaluate observational case-control
studies. We used a self-made rating scale for quality assessment,
which was modified from previous studies [52–54]. Studies
included in this meta-analysis were classified into high quality
($7) or low quality (,7) according to the quality score. The
combined results showed that the null genotype of GSTM1
polymorphism was associated with an increased risk of cervical
neoplasia in both high quality studies and low quality studies.
However, there was lack of association between GSTT1
polymorphism and cervical neoplasia risk either in high quality
studies or in low quality studies. These findings denote that
GSTM1 plays much more important roles than GSTT1 in the
development of cervical neoplasia.
The hypothesis of cigarette smoking being a risk factor for
cervical cancer was originally presented in 1977 [63]. Subse-
quently, amounts of epidemiological studies reported the support
for this hypothesis [7,64–69]. Despite the mechanism that tobacco
smoking increase the risk of uterine cervical cancer remains
unknown, it is believed that the occurrence of tobacco-initiated
DNA damage in the cervical epithelium may be responsible for
malignant transformation [70]. Tobacco smoke contains over fifty
known carcinogens, such as polynuclear aromatic hydrocarbons,
aromatic amines, nicotine, and nitrosamine 4-(methylnitrosa-
mino)-1-(3-pyridyl) -1-butanone (NNK) [70–73]. The concentra-
tions of NNK in cervical mucous of cigarette smoking women
were three times higher than those in non-smokers [70]. Such
carcinogens may promote cancer through the stimulation of cell
division or impairment of local immunosurveillance in the cervical
epithelial tissue [67,74]. In view of the crucial role that the
smoking play in the etiology of cervical cancer, the effect of the
interaction of GSTM1 and GSTT1 polymorphisms and smoking on
the development of cervical neoplasia has been conducted in
several studies [31–33,37,38,46]. Therefore, it is necessary to
analyze quantitatively the association between gene-environment
interaction and the risk of cervical neoplasia using a meta-analysis.
However, no evidence of correlation was observed between
GSTM1 and GSTT1 polymorphisms and cervical neoplasia in
combination with smoking habit. There may be a high risk of false
negative results due to insufficient statistical power with very
limited subjects eligible in this meta-analysis (for GSTM1
polymorphism: 737 cases and 704 controls; for GSTT1 polymor-
phism: 403 cases and 373 controls).
Persistent HPV infections are known to be the major cause of
cervical cancer [5,6]. Therefore, HPV infection status was also
examined in subgroup analysis. Nevertheless, we failed to find any
association between GSTM1 and GSTT1 polymorphisms and
cervical neoplasia risk in either HPV positive women or HPV
negative women. The null result may be owing to limited relevant
studies included in this meta-analysis. Thus, large-scale prospec-
tive cohort studies are needed to provide the best evidence for the
impact of interaction of gene-environment on the risk of cervical
neoplasia.
Over the past decades, a large number of meta-analyses have
been done to investigate the association between GSTM1 and
GSTT1 polymorphisms and variouscancers, including brain tumors
[75], hepatocellular carcinoma [76,77], colorectal cancer [78,79],
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93], lung cancer [94–99], esophageal cancer [100,101], prostate
cancer [102,103], nasopharyngeal carcinoma [104], head and neck
cancer [105], oral and laryngeal cancer [106–108], and acute
leukaemia [109,110]. During revision of the manuscript, a similar
report investigating the association between GSTM1 and GSTT1
polymorphisms and cervical cancer risk was published [111]. In the
report, Economopoulos et al. identified publications by a search of
Medline database (last search: August 3, 2009) and found that the
GSTM1 polymorphism but not GSTT1 polymorphism was
associated with the risk of cervical cancer [111]. In this meta-
analysis, the eligible studies were identified by computer-based
searches of three additional databases (i.e., EMBASE, ISI, and
CBM) besides Medline, and the last search was performed up to
August 2010. Moreover, studies examining the association between
GSTM1 and GSTT1 polymorphisms and cervical intraepithelial
neoplasia were also selected. Much more eligible studies, therefore,
were included in this meta-analysis. Consistent with the results
reported by Economopoulos et al., we found that the null genotype
of GSTM1 polymorphism was associated with a significantly
increased risk of cervical neoplasia. Inconsistent with the results
reported by Economopoulos et al., we found an evidence of an
association between GSTT1 polymorphism and the risk of cervical
neoplasia with a borderline statistical significance. Larger sample
size in this study may be responsible for the positive results. Our
findings were in agreement with several previous reports. For
example, Wang et al. reported that both GSTM1 and GSTT1
polymorphisms are associated with increased risk of hepatocellular
carcinoma [77]. Economopoulos et al. reported that both GSTM1
and GSTT1 null genotype carriers exhibited higher colorectal
cancer risk in Caucasian population [78]. In contrast, some
researchers reported that GSTM1 and GSTT1 polymorphisms did
not increase a substantial risk of breast cancer [88] and prostate
cancer [102]. Taken together, these results indicate that GSTM1
and GSTT1 homozygous deletion polymorphisms may yield
different effects on different types of cancers.
Our study has some limitations. Firstly, the between-study
heterogeneity is a major problem in this meta-analysis because
obvious heterogeneity was detected in overall analyses and also
subgroup analyses. We explored several possible sources of
heterogeneity, including cancer type, ethnicity, sample size, DNA
source for genotyping and quality score. Unfortunately, we failed to
find a bright reason for this variation, indicating that unknown
confoundingvariablesinsinglestudiesmayhavebiasedthe findings.
A conservative manner should, therefore, be adopted to interpret
these results. Secondly, some potential confounding factors, such as
age, sexual habits, and menopausal status can not be ruled out due
to unadjusted data used. Finally, the sample size is relativelysmall in
the meta-analysis, especially in some subgroup analyses.
In summary, this meta-analysis indicates that the null genotypes
of GSTM1 and GSTT1 polymorphisms were associated with a
significantly increased risk of cervical neoplasia. In GSTM1-
GSTT1 interaction analysis, individuals with dual null genotype
were associated with a significantly increased risk of cervical
neoplasia. In gene-environment interaction analysis, neither
smoking status nor HPV infection status was associated with
GSTM1 and GSTT1 polymorphisms. To ensure a precise estimate
of the effect of GSTM1 and GSTT1 polymorphisms on cervical
neoplasia risk, additional unbiased studies with larger sample size
are needed. Such studies will not only elucidate the pivotal roles
GSTM1 and GSTT1 polymorphisms playing in the development of
cervical neoplasia, but also increase our understanding the etiology
of cervical neoplasia.
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